Re: Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal Status
Open Access
- 15 July 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 90 (14) , 1099-1100
- https://doi.org/10.1093/jnci/90.14.1099
Abstract
Early occult spread of tumor cells must be regarded as a major cause for the development of metastatic disease in patients with completely resected breast cancer. Immunocytochemical assays with monoclonal antibodies directed against epithelial differentiation antigens have allowed the detection of micrometastatic carcinoma cells in bone marrow. Most of the studies were performed with monoclonal antibodies either against cytokeratin (a major constituent of the cytoskeleton in epithelial cells) or against membranebound mucins (e.g., epithelial membrane antigen, human milk fat globule, and tumor-associated glycoprotein-12 [TAG12]).Keywords
This publication has 6 references indexed in Scilit:
- Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.Journal of Clinical Oncology, 1998
- Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 WorkshopTumor Biology, 1998
- Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal StatusJNCI Journal of the National Cancer Institute, 1996
- Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastasesThe Lancet, 1996
- Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone MarrowJournal of Hematotherapy, 1994
- Cytokeratin-immunoreactive cells of human lymph nodes and spleen in normal and pathological conditionsVirchows Archiv, 1990